Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11419411 | 0.86 | LDHA (0.57) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL30797834 | 0.84 | SLC6A4 (0.55) | — | |
| SCHEMBL2559132 | 0.84 | SLC6A4 (0.55) | — | |
| SCHEMBL1083505 | 0.81 | HTR2A (0.45) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL1048328 | 0.81 | PNMT (0.46) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL1067852 | 0.81 | HTR1A (0.45) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL1047459 | 0.81 | MMP1 (0.44) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL16151510 | 0.80 | FOS (0.66) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL6126233 | 0.80 | FOS (0.51) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL1047457 | 0.80 | TAAR1 (0.50) | FOSTTRJUNNR3C1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-2884962-B1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INT LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20150216799-A1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC | 2015-08-06 | — | — | US | claimed |
| EP-2884962-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | Smartek International LLC (US) | 2015-06-24 | — | — | EP | claimed |
| WO-2014028796-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC (US) | 2014-02-20 | — | — | WO | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-2104493-A2 | USE OF I) A POLYGLYCOL AND N) AN ACTIVE DRUG SUBSTANCE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR I) MITIGATING THE RISK OF ALCOHOL INDUCED DOSE DUMPING AND/OR II) REDUCING THE RISK OF DRUG ABUSE | Egalet A/S (DK) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008086804-A2 | USE OF I) A POLYGLYCOL AND N) AN ACTIVE DRUG SUBSTANCE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR I) MITIGATING THE RISK OF ALCOHOL INDUCED DOSE DUMPING AND/OR II) REDUCING THE RISK OF DRUG ABUSE | EGALET A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | FOS 588/4885TTR 4185/4885JUN 2687/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | FOS 1847/4885TTR 3433/4885JUN 1850/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | FOS 831/4885TTR 3684/4885JUN 4522/4885 |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR2, HCRTR1, HTR2A | FOS 934/4885TTR 3103/4885JUN 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.